Bruno Hoen1, Bruno Schaub1, Anna L Funk1, Vanessa Ardillon1, Manon Boullard1, André Cabié1, Caroline Callier1, Gabriel Carles1, Sylvie Cassadou1, Raymond Césaire1, Maylis Douine1, Cécile Herrmann-Storck1, Philippe Kadhel1, Cédric Laouénan1, Yoann Madec1, Alice Monthieux1, Mathieu Nacher1, Fatiha Najioullah1, Dominique Rousset1, Catherine Ryan1, Kinda Schepers1, Sofia Stegmann-Planchard1, Benoît Tressières1, Jean-Luc Voluménie1, Samson Yassinguezo1, Eustase Janky1, Arnaud Fontanet1. 1. From INSERM Centre d'Investigation Clinique 1424 (B.H., C.C., B.T.), Service de Maladies Infectieuses et Tropicales, Dermatologie, Médecine Interne (B.H., K.S.), Cellule d'Intervention en Région (CIRE) Antilles, Santé Publique France (S.C.), Laboratoire de Microbiologie (C.H.-S.), Service de Gynécologie Obstétrique (P.K.), Centre Pluridisciplinaire de Diagnostic Prénatal (C.R.), and Pôle Parent-Enfant (E.J.), Centre Hospitalier Universitaire (CHU) de Pointe-à-Pitre/Abymes, and Université des Antilles et de la Guyane, Faculté de Médecine Hyacinthe Bastaraud (B.H.), Pointe-à-Pitre, Guadeloupe; Centre Pluridisciplinaire de Diagnostic Prénatal, Maison de la Femme de la Mère et de l'Enfant (B.S.), INSERM Centre d'Investigation Clinique (M.B., A.C.), Centre de Ressources Biologiques (R.C.), Unit of Obstetrics and Gynecology, Maison de la Femme de la Mère et de l'Enfant (A.M., J.-L.V.), and Laboratoire de Virologie (F.N.), CHU Martinique, Fort-de-France, Martinique; the Emerging Diseases Epidemiology Unit (A.L.F., Y.M., A.F.) and Center for Global Health (A.F.), Institut Pasteur, INSERM, IAME (Infection, Antimicrobials, Modeling, Evolution), Paris Diderot University (C.L.), and Conservatoire National des Arts et Métiers, Unité Pasteur-Cnam Risques Infectieux et Émergents (A.F.), Paris; CIRE de Guyane, Santé Publique France (V.A.), Pôle Mère-Enfant, Centre Hospitalier de l'Ouest Guyanais (G.C.), INSERM Centre d'Investigation Clinique 1424 (M.D., M.N.), Laboratoire de Virologie, Institut Pasteur de la Guyane (D.R.), and Service de Gynécologie Obstétrique, Centre Hospitalier de Cayenne (S.Y.), French Guiana; and Unité de Maladies Infectieuses, Centre Hospitalier Louis Constant Fleming, St. Martin (S.S.-P.) - all in France.
Abstract
BACKGROUND: The risk of congenital neurologic defects related to Zika virus (ZIKV) infection has ranged from 6 to 42% in various reports. The aim of this study was to estimate this risk among pregnant women with symptomatic ZIKV infection in French territories in the Americas. METHODS: From March 2016 through November 2016, we enrolled in this prospective cohort study pregnant women with symptomatic ZIKV infection that was confirmed by polymerase-chain-reaction (PCR) assay. The analysis included all data collected up to April 27, 2017, the date of the last delivery in the cohort. RESULTS: Among the 555 fetuses and infants in the 546 pregnancies included in the analysis, 28 (5.0%) were not carried to term or were stillborn, and 527 were born alive. Neurologic and ocular defects possibly associated with ZIKV infection were seen in 39 fetuses and infants (7.0%; 95% confidence interval, 5.0 to 9.5); of these, 10 were not carried to term because of termination of pregnancy for medical reasons, 1 was stillborn, and 28 were live-born. Microcephaly (defined as head circumference more than 2 SD below the mean for sex and gestational age) was detected in 32 fetuses and infants (5.8%), of whom 9 (1.6%) had severe microcephaly (more than 3 SD below the mean). Neurologic and ocular defects were more common when ZIKV infection occurred during the first trimester (24 of 189 fetuses and infants [12.7%]) than when it occurred during the second trimester (9 of 252 [3.6%]) or third trimester (6 of 114 [5.3%]) (P=0.001). CONCLUSIONS: Among pregnant women with symptomatic, PCR-confirmed ZIKV infection, birth defects possibly associated with ZIKV infection were present in 7% of fetuses and infants. Defects occurred more frequently in fetuses and infants whose mothers had been infected early in pregnancy. Longer-term follow-up of infants is required to assess any manifestations not detected at birth. (Funded by the French Ministry of Health and others; ClinicalTrials.gov number, NCT02916732 .).
BACKGROUND: The risk of congenital neurologic defects related to Zika virus (ZIKV) infection has ranged from 6 to 42% in various reports. The aim of this study was to estimate this risk among pregnant women with symptomatic ZIKV infection in French territories in the Americas. METHODS: From March 2016 through November 2016, we enrolled in this prospective cohort study pregnant women with symptomatic ZIKV infection that was confirmed by polymerase-chain-reaction (PCR) assay. The analysis included all data collected up to April 27, 2017, the date of the last delivery in the cohort. RESULTS: Among the 555 fetuses and infants in the 546 pregnancies included in the analysis, 28 (5.0%) were not carried to term or were stillborn, and 527 were born alive. Neurologic and ocular defects possibly associated with ZIKV infection were seen in 39 fetuses and infants (7.0%; 95% confidence interval, 5.0 to 9.5); of these, 10 were not carried to term because of termination of pregnancy for medical reasons, 1 was stillborn, and 28 were live-born. Microcephaly (defined as head circumference more than 2 SD below the mean for sex and gestational age) was detected in 32 fetuses and infants (5.8%), of whom 9 (1.6%) had severe microcephaly (more than 3 SD below the mean). Neurologic and ocular defects were more common when ZIKV infection occurred during the first trimester (24 of 189 fetuses and infants [12.7%]) than when it occurred during the second trimester (9 of 252 [3.6%]) or third trimester (6 of 114 [5.3%]) (P=0.001). CONCLUSIONS: Among pregnant women with symptomatic, PCR-confirmed ZIKV infection, birth defects possibly associated with ZIKV infection were present in 7% of fetuses and infants. Defects occurred more frequently in fetuses and infants whose mothers had been infected early in pregnancy. Longer-term follow-up of infants is required to assess any manifestations not detected at birth. (Funded by the French Ministry of Health and others; ClinicalTrials.gov number, NCT02916732 .).
Authors: Ai-Ris Y Collier; Erica N Borducchi; Abishek Chandrashekar; Edward Moseley; Lauren Peter; Nicholas S Teodoro; Joseph Nkolola; Peter Abbink; Dan H Barouch Journal: Am J Reprod Immunol Date: 2020-07-01 Impact factor: 3.886
Authors: Christie L Walker; Audrey A Merriam; Eric O Ohuma; Manjiri K Dighe; Michael Gale; Lakshmi Rajagopal; Aris T Papageorghiou; Cynthia Gyamfi-Bannerman; Kristina M Adams Waldorf Journal: Am J Obstet Gynecol Date: 2018-05-05 Impact factor: 8.661
Authors: Koen K A Van Rompay; Rebekah I Keesler; Amir Ardeshir; Jennifer Watanabe; Jodie Usachenko; Anil Singapuri; Christina Cruzen; Eliza Bliss-Moreau; Ashley M Murphy; JoAnn L Yee; Helen Webster; Maria Dennis; Tulika Singh; Holly Heimsath; Danilo Lemos; Jackson Stuart; Kaitlyn M Morabito; Bryant M Foreman; Katherine E Burgomaster; Amy T Noe; Kimberly A Dowd; Erin Ball; Kevin Woolard; Pietro Presicce; Suhas G Kallapur; Sallie R Permar; Kathryn E Foulds; Lark L Coffey; Theodore C Pierson; Barney S Graham Journal: Sci Transl Med Date: 2019-12-18 Impact factor: 17.956
Authors: Julia A Brown; Gursewak Singh; Joshua A Acklin; Silviana Lee; James E Duehr; Anupa N Chokola; Justin J Frere; Kevin W Hoffman; Gregory A Foster; David Krysztof; Richard Cadagan; Adam R Jacobs; Susan L Stramer; Florian Krammer; Adolfo García-Sastre; Jean K Lim Journal: Immunity Date: 2019-02-05 Impact factor: 31.745
Authors: Dawn M Dudley; Matthew T Aliota; Emma L Mohr; Christina M Newman; Thaddeus G Golos; Thomas C Friedrich; David H O'Connor Journal: Annu Rev Virol Date: 2019-06-10 Impact factor: 10.431
Authors: Martha L Ospina; Van T Tong; Maritza Gonzalez; Diana Valencia; Marcela Mercado; Suzanne M Gilboa; Andrea J Rodriguez; Sarah C Tinker; Angelica Rico; Christina M Winfield; Lissethe Pardo; Jennifer D Thomas; Greace Avila; Julie M Villanueva; Sara Gomez; Denise J Jamieson; Franklyn Prieto; Dana Meaney-Delman; Oscar Pacheco; Margaret A Honein Journal: N Engl J Med Date: 2020-08-06 Impact factor: 91.245